The regulatory landscape for actively personalized cancer immunotherapies-Reference-Cited by-同舟云学术

The regulatory landscape for actively personalized cancer immunotherapies

Published:2013-10 Issue:10 Volume:31 Page:880-882
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Britten Cedrik M,Singh-Jasuja Harpreet,Flamion Bruno,Hoos Axel,Huber Christoph,Kallen Karl-Josef,Khleif Samir N,Kreiter Sebastian,Nielsen Michaela,Rammensee Hans-Georg,Sahin Ugur,Hinz Thomas,Kalinke Ulrich

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

http://www.nature.com/articles/nbt.2708.pdf

Reference15 articles.

1. Sjoblom, T. et al. Science 314, 268–274 (2006).

2. Gerlinger, M. et al. N. Engl. J. Med. 366, 883–892 (2012).

3. Castle, J.C. et al. Cancer Res. 72, 1081–1091 (2012).

4. Matsushita, H. et al. Nature 482, 400–404 (2012).

5. Robbins, P.F. et al. Nat. Med. 19, 747–752 (2013).

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine;Vaccine;2024-09

2. An Insight into Immunological Therapeutic Approach against Cancer: Potential Anti-Cancer Vaccines;Current Genomics;2024-08-30

3. Personalized vaccines, novel vaccination technologies, and future prospects;Advanced Vaccination Technologies for Infectious and Chronic Diseases;2024

4. Autologous engineered T cell receptor therapy in advanced cancer;Human Vaccines & Immunotherapeutics;2023-12-15

5. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer;Cancer Immunology Research;2023-05-12